QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Since 1995, it has rapidly expanded from a simple bioanalysis shop to a full service CRO with over 1100 employees in the US, Europe, India and Asia Pacific. Today, it offers expanded pharmaceutical contract R&D services with special expertise in Neuropharmacology, DMPK, Toxicology, Bioanalysis, Translational Medicine, and Early & Late Phase Clinical Research.
Numerous recent acquisitions have strengthened QPS’ preclinical, early and late phase drug development capabilities worldwide. The addition of the DCB toxicology unit in Taiwan and JSW Life Sciences’ neuropharmacology unit in Austria have bolstered QPS’ preclinical services. Expansion of QPS’ Phase I Clinic in the Netherlands and the acquisition of Miami Research Associates (MRA), the largest multi-specialty clinical research center in the United States, have increased QPS’ ability to meet growing early phase clinical market demands. The addition of Qualitix in Taiwan and China, and JSW Clinical Investigations in Austria, have increased QPS’ late phase clinical capabilities and enlarged its Asia Pacific and European presence, enabling the company to participate in the enrollment of global late phase clinical trials with new drug candidates for diverse therapeutic areas.
Through continual enhancements in capacities and resources, QPS stands tall in its commitment to deliver superior quality, skilled performance and trusted service to its valued customers.